Abstract
Conversion to Non-Active Secondary Progressive Multiple Sclerosis (SPMS) in Patients Who Discontinued or Remained on Natalizumab in the Real-World TYSABRI Observational Program (TOP) (2505)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
